4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · IEX Real-Time Price · USD
25.39
+1.46 (6.10%)
May 1, 2024, 4:00 PM EDT - Market closed
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 147 employees on December 31, 2023. The number of employees increased by 7 or 5.00% compared to the previous year.
Employees
147
Change (1Y)
7
Growth (1Y)
5.00%
Revenue / Employee
$140,973
Profits / Employee
-$685,966
Market Cap
1.30B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 147 | 7 | 5.00% |
Dec 31, 2022 | 140 | 16 | 12.90% |
Dec 31, 2021 | 124 | 41 | 49.40% |
Dec 31, 2020 | 83 | 26 | 45.61% |
Jun 30, 2019 | 57 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Brookdale Senior Living | 36,000 |
Omnicell | 3,650 |
NovoCure | 1,453 |
Pacira BioSciences | 712 |
Xencor | 280 |
Ironwood Pharmaceuticals | 267 |
Verona Pharma | 79 |
Ligand Pharmaceuticals | 58 |
FDMT News
- 20 hours ago - 4DMT Announces Presentations at ARVO 2024 Annual Meeting - GlobeNewsWire
- 4 weeks ago - 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis - GlobeNewsWire
- 2 months ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - 4DMT Reports Full Year 2023 Financial Results and Operational Highlights - GlobeNewsWire
- 2 months ago - 4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024 - GlobeNewsWire
- 3 months ago - 4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - 4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - 4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes' - Reuters